WELL Health and HEALWELL AI have announced the expansion of a multi-year agreement that will allow them to launch and manage clinical trial sites at WELL Health clinic locations across Canada. Leveraging HEALWELL’s contract research organization (CRO) capabilities and WELL Health’s network of clinics across Canada positions this partnership as a strong player in AI-driven clinical trials and opens up new revenue streams .
This partnership will enable HEALWELL AI to provide end-to-end vertically integrated services, including patient identification and recruitment, clinical trial architecture and execution, and clinical research data analysis.
Providing clinical trial facilities within WELL Health clinics transforms these clinics into hubs of innovation, improving access and directly benefiting patients by bringing experimental treatments to local sites.
Launching and managing clinical trial sites at WELL Health clinics across Canada will be a powerful strategic initiative. This will allow WELL Health and HEALWELL to leverage their combined strengths in healthcare infrastructure and AI technology, potentially changing the landscape of clinical research.
Vancouver, British Columbia and Toronto, Ontario — (Newsfile Corp. – October 29, 2024) – WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (“WELL”) is a technology-focused is a digital health company. HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (“HEALWELL”) is a healthcare technology company focused on AI and data science for preventive care and services that enable healthcare providers. is a joint venture that will enable WELL and HEALWELL to launch and manage clinical trial sites at WELL clinics across Canada. Leveraging the nation’s largest network of primary care and specialty care clinics, with more than 180 clinics and thousands of healthcare professionals, HEALWELL and WELL will collaborate to expand clinical trials to more patients than ever before. We will continue to expand access to. WELL and HEALWELL aim to transform the clinical research landscape by combining their strengths in healthcare infrastructure and AI technology.
This partnership will enable HEALWELL AI to provide end-to-end vertically integrated services, from patient recruitment to clinical trial conduct and clinical research data analysis. By including WELL Health Diagnostic Centers (WHDC) and its robust specialty care patient roster, including cardiology, radiology, sleep medicine, and endocrinology, this partnership leverages valuable patient data to Necessary research in cardiovascular diseases and their comorbidities can be strengthened. Interest is important. For WELL, hosting clinical trials within the clinic transforms the clinic into a hub of innovation, bringing experimental treatments to local facilities and directly benefiting patients by improving access. By leveraging HEALWELL’s clinical infrastructure and HEALWELL’s contract research organization (CRO) capabilities, this partnership positions itself as a strong player in AI-driven clinical trials and drives new revenue potential. Masu.
story continues
Dr. Michael Frankel, Chief Medical Officer of WELL, said: “Launching and managing clinical trial sites at WELL clinics across Canada is a powerful and transformative strategic initiative. and HEALWELL will be able to leverage the combined strengths of both companies in healthcare infrastructure.” AI technology has the potential to change the landscape of clinical research. ”
Dr. Alexander Dobranovskiy, CEO of HEALWELL, said: “Patient identification and recruitment for clinical trials is an increasingly complex challenge in the global healthcare and life sciences sector. “It also depends on effective patient recruitment and management.” Participation – a step that leads to improved outcomes for patients, healthcare professionals, and the entire health system Through our established late-stage CRO, Canadian Phase Onward, HEALWELL has already made great strides in accelerating the recruitment process, but WELL Clinic’s Our network is also expanding. Ultimately, this service will reduce the costs and timelines of clinical trials while benefiting physicians, healthcare professionals, and patients alike. ”
Strategic benefits of partnerships include:
Improving access to clinical trials: With WELL’s extensive and growing network of more than 180 family and specialty clinics across the country, patients in Canada’s diverse regions can now more conveniently access clinical trials. Masu. This broad scope supports recruitment for a wide range of clinical trial programs, from general therapeutic areas to highly specialized conditions. HEALWELL focuses on recruiting niche patient populations, including those with rare diseases, specific genetic profiles, or unique demographic backgrounds. This focus increases the feasibility and comprehensiveness of clinical trials and allows sponsors to explore treatments for unmet medical needs. As a result, clinical trials involve more patients, collect more representative data, and ultimately strengthen the value and relevance of clinical research findings.
Improving efficiency with AI-driven solutions: HEALWELL’s focus on advanced AI and data science is expected to streamline clinical trial processes, from patient recruitment to data analysis. AI-driven tools can also help identify eligible participants, predict outcomes, and shorten trial duration by automating data collection and analysis, making the process more efficient and cost-effective. .
Strengthening our position in the healthcare innovation market: WELL and HEALWELL establish themselves as leaders in the emerging field of digital healthcare solutions for research by establishing a unique niche in AI-powered clinical trials I’m doing it. These efforts strengthen our partnerships with pharmaceutical companies and other research institutions looking to leverage AI to optimize clinical trials, contributing to financial growth and technology development.
Data-driven insights for future healthcare innovations: Conducting large-scale clinical trials generates valuable real-world data that can inform future healthcare innovations. These insights support HEALWELL AI’s goal to enhance disease detection and preventive care tools, creating a cycle of continuous improvement that benefits both clinical outcomes and business goals.
Hamed Shabaji
Chairman and CEO
Well Health Technologies Co., Ltd.
Dr. Alexander Dobranovsky
chief executive officer
Hellwell AI Co., Ltd.
About WELL Health Technologies Corp.
WELL’s mission is to enable healthcare providers with technology. We do this by developing the best available technology, services and support to enable healthcare providers to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes a wide range of front and back-office management software applications that help physicians operate and secure their practices. WELL’s solutions provide access to more than 37,000 healthcare providers across the U.S. and Canada, a Canadian-owned and operated company with more than 180 clinics supporting primary care, specialty care, and diagnostic services. Power the largest healthcare ecosystem in the world. In the United States, WELL’s solutions focus on specialty markets such as gastrointestinal markets, women’s health, primary care, and mental health. WELL is listed on the Toronto Stock Exchange under the symbol “WELL” and on OTC exchanges under the symbol “WHTCF.” For more information about WELL, please visit www.well.company.
About Health Well AI
HEALWELL is a healthcare technology company focused on AI and data science for preventive care. Its mission is to improve health care and save lives through early detection and detection of disease. The company uses its proprietary technology to develop advanced clinical decision support systems that help healthcare providers detect rare and chronic diseases, improve practice efficiency, and ultimately improve patient health outcomes. We are developing and commercializing. HEALWELL is implementing a strategy centered on developing and acquiring technical and clinical science capabilities that complement the company’s roadmap. HEALWELL is listed on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on OTC exchanges under the symbol “HWAIF.” For more information about HEALWELL, please visit https://healwell.ai/.
Forward-looking statements
Certain statements in this press release constitute “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. . This includes the potential benefits of utilizing WELL’s clinic network for HEALWELL clinical testing. ordeal. Forward-looking statements are necessarily based on management’s perception of technical capabilities and anticipated benefits, which are believed to be reasonable by Well and Healthwell as of the date of such statements. are beyond Well and HealthWell’s control and are inherently subject to business, economic and competitive uncertainties. and contingencies that may cause forward-looking statements to ultimately turn out to be inaccurate or false, in whole or in part. The forward-looking statements contained in this press release affect our ability to identify and recruit patients, our ability to obtain all necessary governmental consents to conduct clinical trials at such clinics, and the expectations of pharmaceutical sponsors for clinical trials. It is based on various assumptions, including but not limited to obtaining consent. It will be conducted at Wells Clinic.
Many known and unknown risk factors are beyond the control of WELL and HEALWELL, which could cause actual benefits and integration plans to differ materially from the results suggested by such forward-looking statements. Such risk factors include failure to obtain necessary governmental or research ethics committee consents, failure to successfully identify candidate patients for clinical trials, and failure to recruit interested physicians to support such clinical trials. and the other risks described in the section titled “Risk Factors.” “WELL and HEALWELL’s most recent annual information form, which is available on each company’s SEDAR+ profile at www.sedarplus.ca. Risk factors that may impact WELL and HEALWELL Readers should carefully consider these and other factors, uncertainties and potential events, and read forward-looking statements unduly. You are cautioned not to rely on forward-looking statements as there can be no assurance that they will prove to be accurate. WELL and HEALWELL are provided for the purpose of providing information regarding management’s expectations and plans regarding the future.WELL and HEALWELL may update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We disclaim any intention or obligation to describe material differences between actual events and such forward-looking statements to the extent required by applicable law. All are subject to these warning statements.
For more information:
tyler baba
Investor Relations Manager
Well Health Technologies Co., Ltd.
Phone: 604-628-7266
investor@well.company
Pardeep S. Sangha
Investor information
Hellwell AI Co., Ltd.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228165.
